Genetic discoveries and treatment advances in neuroblastoma

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current opinion in pediatrics

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/MOP.0000000000000296PMID 26576010PMCID PMC4731097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of radiation therapy on height and spine MRI characteristics in children with neuroblastoma.

  2015cited by this paper
• Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

  2015cited by this paper
• Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

  2015cited by this paper
• Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

  2015cited by this paper
• Second malignancies in patients with neuroblastoma: The effects of risk‐based therapy

  2015cited by this paper
• CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus.

  2015cited by this paper
• Mutational dynamics between primary and relapse neuroblastomas

  2015cited by this paper
• Recent insights into the biology of neuroblastoma

  2014cited by this paper
• ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

  2014cited by this paper
• Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.

  2014cited by this paper
• Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ system

  2014cited by this paper
• GD2-targeted immunotherapy and radioimmunotherapy.

  2014cited by this paper
• Emergence of new ALK mutations at relapse of neuroblastoma.

  2014cited by this paper
• Diverse Solid Tumors Expressing a Restricted Epitope of L1-CAM Can Be Targeted by Chimeric Antigen Receptor Redirected T Lymphocytes

  2014cited by this paper
• Rare variants in TP53 and susceptibility to neuroblastoma.

  2014cited by this paper
• Advances in chimeric antigen receptor immunotherapy for neuroblastoma.

  2013cited by this paper
• Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641

  2013cited by this paper
• Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.

  2013cited by this paper
• Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility.

  2013cited by this paper
• The genetic landscape of high-risk neuroblastoma

  2013cited by this paper
• Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.

  2013cited by this paper
• Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.

  2012cited by this paper
• Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

  2012cited by this paper
• A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants: A Children's Oncology Group Study

  2012cited by this paper
• Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

  2012cited by this paper
• Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.

  2012cited by this paper
• Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma

  2012cited by this paper
• Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

  2012cited by this paper
• Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival.

  2012cited by this paper
• Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

  2012cited by this paper
• Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

  2012cited by this paper
• Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.

  2011cited by this paper
• Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)

  2011cited by this paper
• Genome-Wide Linkage Analysis to Identify Genetic Modifiers of ALK Mutation Penetrance in Familial Neuroblastoma

  2011cited by this paper
• miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples

  2011cited by this paper
• Immunotherapy Targets in Pediatric Cancer

  2011cited by this paper
• Integrative genomics identifies LMO1 as a neuroblastoma oncogene

  2011cited by this paper
• Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.

  2010cited by this paper
• A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients

  2010cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• Accumulation of segmental alterations determines progression in neuroblastoma.

  2010cited by this paper
• Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

  2010cited by this paper
• Myc proteins as therapeutic targets

  2010cited by this paper
• Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

  2010cited by this paper
• Overall genomic pattern is a predictor of outcome in neuroblastoma.

  2009cited by this paper
• Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

  2009cited by this paper
• The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

  2009cited by this paper
• Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma.

  2009cited by this paper
• Disrupting Polyamine Homeostasis as a Therapeutic Strategy for Neuroblastoma

  2009cited by this paper
• Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group

  2008cited by this paper
• Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

  2005cited by this paper

• MS275 Inhibits Neuroblastoma Cell Growth by Mediating H3K27ac/PROX1 Axis In Silico and In Vitro

  2025cites this paper
• Targeting Pathways in Neuroblastoma: Advances in Treatment Strategies and Clinical Outcomes

  2025cites this paper
• Refractory and Relapsed Neuroblastoma: Exploring New Treatment Methods to Improve Outcomes

  2025cites this paper
• Exploring Pediatric Neuroblastoma: A Comprehensive Analysis of Adrenal and Nonadrenal Tumor Characteristics in the United States

  2025influential citation
• A 3-year-old child with multifocal primary (thoracoabdominal) neuroblastoma- A case report and review of literature

  2024cites this paper
• UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis

  2023cites this paper
• LINC00460 promotes neuroblastoma tumorigenesis and cisplatin resistance by targeting miR-149-5p/DLL1 axis and activating Notch pathway in vitro and in vivo

  2023cites this paper
• CircRANBP17 modulated KDM1A to regulate neuroblastoma progression by sponging miR-27b-3p

  2023cites this paper
• MYCN amplification and International Neuroblastoma Risk Group stratification on fine-needle aspiration biopsy and their correlation to survival in neuroblastoma

  2022cites this paper
• ViLoN—a multi-layer network approach to data integration demonstrated for patient stratification

  2022cites this paper
• Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease

  2022cites this paper
• Neuroblastoma: Essential genetic pathways and current therapeutic options.

  2022cites this paper
• Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma

  2022cites this paper
• Allele-specific expression links diverse cis-regulatory mutations to recurrent gene dysregulation in high-risk neuroblastoma

  2021cites this paper
• Development and Validation of a Lncrnas-Based Nomogram for Survival Prediction in Neuroblastoma Patients

  2021cites this paper
• Association of Genetic Polymorphisms and Serum Levels of IL-6 and IL-8 with the Prognosis in Children with Neuroblastoma

  2021cites this paper
• The glycosphingolipid GD2 as an effective but enigmatic target of passive immunotherapy in children with aggressive neuroblastoma (HR-NBL).

  2020cites this paper
• Incidence and outcomes of neuroblastoma in Australian children: A population‐based study (1983–2015)

  2020cites this paper
• Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting

  2020cites this paper
• YM155-Adapted Cancer Cell Lines Reveal Drug-Induced Heterogeneity and Enable the Identification of Biomarker Candidates for the Acquired Resistance Setting

  2020cites this paper
• MYC-associated protein X binding with the variant rs72780850 in RNA helicase DEAD box 1 for susceptibility to neuroblastoma

  2020cites this paper
• Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma

  2020cites this paper
• Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma

  2020cites this paper
• Associations between WTAP gene polymorphisms and neuroblastoma susceptibility in Chinese children

  2020cites this paper
• ijms-648549 2nd Revision by Ugo Rovigatti

  2020cites this paper
• miR‐15a‐5p, miR‐15b‐5p, and miR‐16‐5p inhibit tumor progression by directly targeting MYCN in neuroblastoma

  2019cites this paper
• Genetic markers in neuroblastoma

  2019cites this paper
• The Evolution of Risk Classification for Neuroblastoma

  2019cites this paper
• TP53 gene rs1042522 allele G decreases neuroblastoma risk: a two-centre case-control study

  2019cites this paper
• Transcriptome profiling reveals the role of ZBTB38 knock-down in human neuroblastoma

  2019cites this paper
• Anti‐tumor effect of sulfasalazine in neuroblastoma

  2019cites this paper
• Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.

  2019cites this paper
• Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.

  2019cites this paper
• Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma

  2019cites this paper
• Lack of associations between AURKA gene polymorphisms and neuroblastoma susceptibility in Chinese children

  2018cites this paper
• The protective autophagy activated by GANT-61 in MYCN amplified neuroblastoma cells is mediated by PERK

  2018cites this paper
• A review of neuroblastoma: prevalence, diagnosis, related genetic factors, and treatment

  2018cites this paper
• GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models

  2018cites this paper
• DUSP5 expression associates with poor prognosis in human neuroblastoma.

  2018cites this paper
• Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children

  2018cites this paper
• Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells

  2018cites this paper
• RSRC1 and CPZ gene polymorphisms with neuroblastoma susceptibility in Chinese children.

  2018cites this paper
• Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

  2017cites this paper
• Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma

  2017cites this paper
• Seltene Tumordispositionssyndrome mit Manifestation im Kindesalter

  2017cites this paper
• The effects of selective inhibitors of N-Glycosylation and Endoplasmic Reticulum stress inducers on Neuroblastoma cell proliferation and Apoptosis

  2017cites this paper
• Recent biologic and genetic advances in neuroblastoma: Implications for diagnostic, risk stratification, and treatment strategies.

  2016cites this paper
• Neuroblastoma: A Tough Nut to Crack.

  2016cites this paper
• Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.

  2016cites this paper
• High‐risk neuroblastoma: challenges in management in low‐ and middle‐income countries

  2016cites this paper
• Documentation of Our Neuroblastoma Cases ( 49 Cases, Retrospective Study)

  2016influential citation
• The Influences of Chemotherapeutics on the Cell Cycle in SKN-SH Neuroblastoma Cells and Clinic Significance

  2016cites this paper
• Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.

  2014cites this paper